Infusion Nurses Society’s Post

I am very proud of the International Myeloma Foundation new video series featuring Joseph Mikhael. We have lots of great videos coming over the next few weeks, but I wanted to share 3 key things (there were more, but let’s stick to 3 for the sake of a LinkedIn post) that we took into consideration when developing this series. 1. We need to make education fun, especially when posting to social media. #Edutainment 2. We need to adapt content per channel. Since LinkedIn and other social media platforms play videos without sound by default, we must include captions. It’s a win/win, especially for people like myself who are hard of hearing. 3. We need to encourage conversation with each piece of content. People shouldn’t feel like they’re just being “talked to,” but rather feel empowered to join the discussion. I am deeply grateful to Joseph Mikhael who is a joy to work with and collaborate to deliver content that is both informative as well as engaging. And thank you to Roman Cuilla Martinez I trust Roman to consistently deliver outstanding content and make the production day a joyful experience as well. You are a true collaborator.

The result is highly encouraging, sooner or later, the front line of CAR-T treatment will come. Johnson & Johnson Legend Biotech solidify #Carvykti's lead in earlier multiple myeloma with strong survival showing After putting on a strong performance in preventing disease progression in the earlier treatment of multiple myeloma, Johnson & Johnson and Legend Biotech’s Carvykti has once again mounted a major benefit—this time in prolonging patients’ lives. A single dose of the star BCMA CAR-T therapy significantly slashed the risk of death by 45% compared with two traditional combination treatments in myeloma patients who had received at least one prior line of therapy, according to an update of the phase 3 CARTITUDE-4 trial. Combinations of either Bristol Myers Squibb’s Pomalyst, Takeda’s Velcade and dexamethasone (PVd), or J&J’s Darzalex, Pomalyst and dexamethasone (DPd) served as the trial's comparators. The data were presented at the 2024 International Myeloma Society (IMS) annual meeting after investigators followed patients in CARTITUDE-4 for a median duration of 33.6 months. An earlier data cut from the study, linking Carvykti to a 59% lower risk of disease progression or death, enabled the med's second-line approval from the FDA in April. https://lnkd.in/ei5Gt_pM

Excellent article. It depicts the fallacy, opaqueness, unfairness of PBM’s in cancer care very clearly. We cannot decrease health care costs in oncology without regulating (fairly and transparently): PBM’s, hospital costs, and the 340B program.

" Product of the Day : Defrijet & Anfoe 6000 " Defrijet & Anfoe 6k is a high-quality therapeutic combination designed for critical care. It offers fast-acting relief for patients requiring specialized treatment. Known for its precision and effectiveness, it ensures better patient outcomes. Trusted by healthcare professionals for reliability and efficacy in demanding medical conditions. Share this post & get upto 50% offer ! 🔥 #productoftheday #topproducts #exporters #hospitalpharmacist #prescribed #criticalcaremedicine #oncologist #pharmaproducts [Anfoe 6000 Oncology Support Equipment, Defrijet treats chronic iron, Anfoe 6000IU Injection for kidney disease]

Great read on biosimilars and how they are helping to reduce the cost of healthcare. Rheumatology biosimilars are expanding quickly and we can learn much from how these have been used and reduced costs in Oncology.

Are unlisted J codes causing headaches in your oncology practice's billing process? We outline six best practices to minimize risk and ensure accurate reimbursement, helping you navigate bliing complexities with confidence :http://ow.ly/OtVL30sGL2P #MedicalCoding #RevenueCycleManagement #HealthcareFinance

💊 Formulary Exclusions... what impact will this have on patients? 🔷 The three largest PBM'S (Caremark, Express Scripts and OptumRx) yet again added to their list of drugs they exclude from their standard formularies. 🔷 In 2023, another 600 drugs joined the list. Considering they fill about 80% of total Prescriptions, this is a concern. Ultimately, this leaves providers and patients alike with less choice over medicine. This is especially detrimental to diabetes patients who require insulin. The big 3 have favored Iispro and Humulin or NovoLog and Novolin, but no lower-list price versions of the branded products. Where does this leave patients? Unfortunately, many will be left to pay out of their own pocket for drugs. Antidepressants, cancer treatments, insulin and many other life saving treatments are being abandoned due to price. It will be interesting to see the list at the end of 2024...

CMS is raising the bar for safety and equity in cancer care. Under the Inflation Reduction Act of 2022, Medicare has the authority to negotiate with drug companies to supply its beneficiaries with affordable, life-saving treatments. Moving forward, the CMS is requiring drug companies to justify the value of their products with comprehensive, real-world evidence (RWE). Notably, Medicare wants to know how these drugs affect a range of patient outcomes with data on specific populations of interest. This RWE supports these negotiations in a number of ways: ↳ Identifying therapeutic alternatives ↳ Measuring key patient outcomes ↳ Examining specific populations ↳ Promoting health equity ↳ Highlighting unmet medical needs RWE will be a major asset to life science professionals and patients, alike. This framework is incredibly critical for advancing the field of oncology while upholding the core principles and priorities of #ValueBasedCare. #CMS #Oncology #PharmaceuticalIndustry #USHealthcare #PatientCenteredCare

Happy to share our publication from #amccbs2024 about biosimilar substitution!

A very interesting development in non-invasive diagnosis of idiopathic pulmonary fibrosis (IPF) using and AI-based software. IPF is a deadly disease with an average survival rate of 2 to 5 years after diagnosis. Unfortunately, the two existing FDA-approved drugs have not improved survival rate nor the quality of life for the affected patients. At MAX BioPharma (www.maxbiopharma.com) we are developing an anti-fibrotic and anti-inflammatory orally bioavailable oxysterol-based drug candidate for targeting IPF. We hope that this drug candidate will have much greater efficacy and safety than the existing drugs based on its unique molecular mechanism of action. Philip Sell Jaejin (Joey) Lee Metaba https://lnkd.in/gNyM-2KD